XORTX Therapeutics Inc. reported the voting results from its Annual General and Special Meeting held on March 24, 2026. Shareholders approved key resolutions including setting the board at five directors, electing five directors, appointing Davidson & Co. LLP as auditor, re-approving the stock option plan, and authorizing a share consolidation to regain NASDAQ compliance.
Key takeaways
Shareholders approved setting the number of directors at five with 98.323% for the motion.
Five directors were elected: Allen Davidoff (86.652% for), Mika Grasso (100% for), Anthony J. Giovinazzo (93.578% for), Richard Grieve (100% for), and George Scorsis (100% for).
Davidson & Co. LLP was appointed as auditor with 99.384% approval.
The stock option plan was re-approved with 85.176% support, maintaining a 10% maximum share reserve.
A share consolidation of up to 5:1 was approved with 89.811% for, aimed at regaining NASDAQ Capital Market listing compliance.